Compounding pharmacies are crimping sales of Novo Nordisk’s obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

New Wegovy prescriptions have increased by about 33% since May 22, when a U.S. Food and Drug Administration ban on so-called ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Weight-loss jab Wegovy sees another prescription boost after ban on copycats - Novo CEO ousted in May, in place until ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks.

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...